S&P 500   4,567.33 (+0.27%)
DOW   35,529.20 (+0.32%)
QQQ   391.10 (+0.23%)
AAPL   189.86 (-0.28%)
MSFT   378.03 (-1.22%)
META   333.59 (-1.59%)
GOOGL   135.61 (-1.16%)
AMZN   146.41 (-0.42%)
TSLA   248.78 (+0.83%)
NVDA   481.54 (+0.70%)
NIO   7.23 (+0.28%)
BABA   74.69 (-2.67%)
AMD   124.48 (+2.02%)
T   16.23 (+0.31%)
F   10.64 (+2.60%)
MU   77.23 (+1.46%)
CGC   0.55 (+1.61%)
GE   119.38 (+0.45%)
DIS   92.68 (+0.19%)
AMC   7.04 (+5.07%)
PFE   30.02 (+1.11%)
PYPL   58.54 (+0.12%)
XOM   103.23 (-0.64%)
S&P 500   4,567.33 (+0.27%)
DOW   35,529.20 (+0.32%)
QQQ   391.10 (+0.23%)
AAPL   189.86 (-0.28%)
MSFT   378.03 (-1.22%)
META   333.59 (-1.59%)
GOOGL   135.61 (-1.16%)
AMZN   146.41 (-0.42%)
TSLA   248.78 (+0.83%)
NVDA   481.54 (+0.70%)
NIO   7.23 (+0.28%)
BABA   74.69 (-2.67%)
AMD   124.48 (+2.02%)
T   16.23 (+0.31%)
F   10.64 (+2.60%)
MU   77.23 (+1.46%)
CGC   0.55 (+1.61%)
GE   119.38 (+0.45%)
DIS   92.68 (+0.19%)
AMC   7.04 (+5.07%)
PFE   30.02 (+1.11%)
PYPL   58.54 (+0.12%)
XOM   103.23 (-0.64%)
S&P 500   4,567.33 (+0.27%)
DOW   35,529.20 (+0.32%)
QQQ   391.10 (+0.23%)
AAPL   189.86 (-0.28%)
MSFT   378.03 (-1.22%)
META   333.59 (-1.59%)
GOOGL   135.61 (-1.16%)
AMZN   146.41 (-0.42%)
TSLA   248.78 (+0.83%)
NVDA   481.54 (+0.70%)
NIO   7.23 (+0.28%)
BABA   74.69 (-2.67%)
AMD   124.48 (+2.02%)
T   16.23 (+0.31%)
F   10.64 (+2.60%)
MU   77.23 (+1.46%)
CGC   0.55 (+1.61%)
GE   119.38 (+0.45%)
DIS   92.68 (+0.19%)
AMC   7.04 (+5.07%)
PFE   30.02 (+1.11%)
PYPL   58.54 (+0.12%)
XOM   103.23 (-0.64%)
S&P 500   4,567.33 (+0.27%)
DOW   35,529.20 (+0.32%)
QQQ   391.10 (+0.23%)
AAPL   189.86 (-0.28%)
MSFT   378.03 (-1.22%)
META   333.59 (-1.59%)
GOOGL   135.61 (-1.16%)
AMZN   146.41 (-0.42%)
TSLA   248.78 (+0.83%)
NVDA   481.54 (+0.70%)
NIO   7.23 (+0.28%)
BABA   74.69 (-2.67%)
AMD   124.48 (+2.02%)
T   16.23 (+0.31%)
F   10.64 (+2.60%)
MU   77.23 (+1.46%)
CGC   0.55 (+1.61%)
GE   119.38 (+0.45%)
DIS   92.68 (+0.19%)
AMC   7.04 (+5.07%)
PFE   30.02 (+1.11%)
PYPL   58.54 (+0.12%)
XOM   103.23 (-0.64%)

Nkarta Stock Price, News & Analysis (NASDAQ:NKTX)

$2.48
+0.02 (+0.81%)
(As of 12:22 PM ET)
Compare
Today's Range
$2.47
$2.61
50-Day Range
$1.31
$3.14
52-Week Range
$1.28
$9.20
Volume
123,963 shs
Average Volume
1.05 million shs
Market Capitalization
$121.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67

Nkarta MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
491.4% Upside
$14.67 Price Target
Short Interest
Bearish
14.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.50) to ($2.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

423rd out of 949 stocks

Pharmaceutical Preparations Industry

191st out of 438 stocks


NKTX stock logo

About Nkarta Stock (NASDAQ:NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Stock Price History

NKTX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Raymond James Upgrades Nkarta (NKTX)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
See More Headlines
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NKTX
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.67
High Stock Price Target
$26.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+496.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-113,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.05 per share

Miscellaneous

Free Float
46,324,000
Market Cap
$120.71 million
Optionable
Not Optionable
Beta
-0.11
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Paul J. HastingsMr. Paul J. Hastings (Age 63)
    CEO, President & Director
    Comp: $938.41k
  • Dr. Alicia J. Hager (Age 53)
    Chief Legal Officer & Corporate Secretary
    Comp: $590.94k
  • Ms. Alyssa Levin C.A. (Age 38)
    CPA, Chief Financial & Business Officer and Principal Accounting Officer
  • Dr. Ralph Brandenberger Ph.D. (Age 54)
    Chief Technical Officer
  • Dr. James Trager Ph.D. (Age 60)
    Chief Scientific Officer
  • Mr. Greg Mann
    Vice President of Public Affairs and Investor Relations
  • Dr. David R. Shook M.D. (Age 45)
    Chief Medical Officer














NKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares.
View NKTX analyst ratings
or view top-rated stocks.

What is Nkarta's stock price target for 2024?

5 analysts have issued twelve-month price objectives for Nkarta's stock. Their NKTX share price targets range from $9.00 to $26.00. On average, they expect the company's share price to reach $14.67 in the next year. This suggests a possible upside of 491.4% from the stock's current price.
View analysts price targets for NKTX
or view top-rated stocks among Wall Street analysts.

How have NKTX shares performed in 2023?

Nkarta's stock was trading at $5.99 at the beginning of 2023. Since then, NKTX stock has decreased by 58.6% and is now trading at $2.48.
View the best growth stocks for 2023 here
.

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our NKTX earnings forecast
.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.06.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

(NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.

Who are Nkarta's major shareholders?

Nkarta's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (1.07%), Northern Trust Corp (0.66%), Monaco Asset Management SAM (0.48%), Innovis Asset Management LLC (0.28%), New York Life Investment Management LLC (0.20%) and Charles Schwab Investment Management Inc. (0.14%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George.
View institutional ownership trends
.

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NKTX) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -